Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593902 · ClinicalTrials.gov registry record · Phase 2
Cardiac Safe Transplants for Systemic Sclerosis
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03593902 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT03593902, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mesna
- DRUG Rituximab
- DRUG rATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-05-17 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03593902
The ClinicalTrials.gov registry entry for NCT03593902 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03593902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03593902 about?
NCT03593902 is a clinical study titled "Cardiac Safe Transplants for Systemic Sclerosis". This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
What is the current status of trial NCT03593902?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-05-17. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT03593902?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mesna (DRUG), Rituximab (DRUG), rATG (DRUG).
Who is sponsoring clinical trial NCT03593902?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.